https://www.selleckchem.com/products/kn-93.html
and the first clinical experiences underline the high potential of integrating FSA with ex-vivo MRI of the fresh surgical specimen. Triggering receptor expressed on myeloid cells (TREM)-1 is a key mediator of innate immunity previously associated with the severity of inflammatory disorders, and more recently, the inferior survival of lung and liver cancer patients. Here, we investigated the prognostic impact and immunological correlates of expression in breast tumors. Breast tumor microarray and RNAseq expression profiles (n=4,364 tumors)